Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma - PubMed (original) (raw)

Review

. 2021 Jul;74(1):491-502.

doi: 10.1002/hep.31653. Epub 2021 Jun 4.

Wenjun Zhang 2, Samira Safarikia 3, Abdulkadir Isidan 2, Angela M Chen 2, Ping Li 2, Heather Francis 1 4, Lindsey Kennedy 1, Leonardo Baiocchi 5, Domenico Alvaro 3, Shannon Glaser 6, Burcin Ekser # 2, Gianfranco Alpini # 1 4

Affiliations

Review

Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma

Keisaku Sato et al. Hepatology. 2021 Jul.

Abstract

Cholangiopathies, such as primary sclerosing cholangitis, biliary atresia, and cholangiocarcinoma, have limited experimental models. Not only cholangiocytes but also other hepatic cells including hepatic stellate cells and macrophages are involved in the pathophysiology of cholangiopathies, and these hepatic cells orchestrate the coordinated response against diseased conditions. Classic two-dimensional monolayer cell cultures do not resemble intercellular cell-to-cell interaction and communication; however, three-dimensional cell culture systems, such as organoids and spheroids, can mimic cellular interaction and architecture between hepatic cells. Previous studies have demonstrated the generation of hepatic or biliary organoids/spheroids using various cell sources including pluripotent stem cells, hepatic progenitor cells, primary cells from liver biopsies, and immortalized cell lines. Gene manipulation, such as transfection and transduction can be performed in organoids, and established organoids have functional characteristics which can be suitable for drug screening. This review summarizes current methodologies for organoid/spheroid formation and a potential for three-dimensional hepatic cell cultures as in vitro models of cholangiopathies.

© 2020 by the American Association for the Study of Liver Diseases.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Generation of hepatic organoids and spheroids. Liver organoids are generally established from ESCs, iPSCs, HPCs, or primary cells isolated from liver or bile duct tissue samples. Cells are embedded with ECM components, such as Matrigel or collagen type I, to support organoid formation. Cells differentiate into hepatic cells depending on culture media. Mature organoids are functional and consist of multiple cell types, such as hepatocytes and cholangiocytes. Hepatocytes in organoids express HNF4α and albumin, as well as show tight junction, bile canaliculi, and CYP3A4 activity. Populating cholangiocytes can form cyst-like structures and have primary cilia and GGT activity expressing biliary markers, such as CK-7 and CK-19. Cell aggregates established from a single cell type, especially immortalized or cancer cells, are referred to as “spheroids.” Spheroid formation can be achieved using scaffold or scaffold-free techniques. Scaffold-free methods inhibit cells to adhere on the bottom surface by hanging drop culture media, constant rotation of flasks, or culture plates with an ultralow attachment surface. Although spheroids do not have multiple cell types, they are suitable for gene manipulation and drug screening tests.

FIG. 2.

FIG. 2.

Generation of liver organoids using isolated human hepatic cells and scaffold-free methods. (A) Left: Representative phase contrast microscopic image showing the isolated human intrahepatic cholangiocyte in culture. Right: Immunofluorescent staining showing CK-19 expression in isolated cholangiocytes. (B) Representative microscopic image showing the formation of liver organoids by coculturing of primary human hepatocytes, cholangiocytes, and LSECs for 14 days at low adhesive plates. (C) Immunofluorescent staining shows the expression of albumin and CYP3A4 in hepatocytes populating the generated organoid. (D) Immunofluorescence shows the expression of AQP1 in LSECs and CK-19 in cholangiocytes populating the organoid. Abbreviation: CHO, cholangiocyte.

FIG. 3.

FIG. 3.

Experimental potentials of hepatic organoids. Generated liver organoids/spheroids are suitable for drug screening and gene manipulation, such as transfection and transduction. Effects can be obtained by RNA sequencing for gene expression profiling, immunofluorescence for protein expression and localization, dose–response curve analysis for drug sensitivity tests, and enzyme-linked immunosorbent assay for protein secretion into culture media. Patient-derived organoids can be used to observe morphology as well as mutation screening to identify gene aberrations. Abbreviation: ELISA, enzyme-linked immunosorbent assay.

References

    1. Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease—a practical approach for translational research. J Hepatol 2020;73:423–440. - PubMed
    1. Brevini T, Tysoe OC, Sampaziotis F. Tissue engineering of the biliary tract and modelling of cholestatic disorders. J Hepatol 2020;73:918–932. - PubMed
    1. Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut 2019;68:2228–2237. - PMC - PubMed
    1. Takebe T, Wells JM. Organoids by design. Science 2019;364:956–959. - PMC - PubMed
    1. Sato K, Glaser S, Kennedy L, Liangpunsakul S, Meng F, Francis H, et al. Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets. Expert Opin Ther Targets 2019;23:461–472. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources